# LOTIS-9 (NCT05144009)

> A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05144009
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: ADC Therapeutics S.A.
- Conditions: Diffuse Large B-cell Lymphoma
- Interventions: Loncastuximab Tesirine; Rituximab
- Enrollment: 41
- Primary outcome: CR Rate
- Primary outcome: Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lotis-9-nct05144009